SCHEMBL5670076

SCHEMBL5670076

c1ccc(-c2cnn(-c3cccc(-c4cccnc4)c3)c2)nc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM5 P41594 6/20 0.62
CYP2A6 P11509 2/20 0.55
HTR1A P08908 1/20 0.43
HTR7 P34969 1/20 0.43
MKNK1 Q9BUB5 3/20 0.42
GRM4 Q14833 2/20 0.41
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
TP53 P04637 1/20 0.41
PKM P14618 1/20 0.41
TSHR P16473 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
PDE10A Q9Y233 1/20 0.41
KDR P35968 1/20 0.40
MEN1 O00255 2/20 0.40
PSIP1 O75475 1/20 0.40
AXL P30530 1/20 0.40
MKNK2 Q9HBH9 1/20 0.40
PIM1 P11309 1/20 0.40
PIM2 Q9P1W9 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5667022 0.89 GRM5 (0.68) GRM5HTR1AHTR7MKNK1GRM4
SCHEMBL5667534 0.89 GRM5 (0.71) GRM5CYP2A6HTR1AHTR7MKNK1
SCHEMBL5669963 0.88 GRM5 (0.64) GRM5CYP2A6HTR1AHTR7MKNK1
SCHEMBL5668114 0.87 CYP2A6 (0.58) GRM5CYP2A6GRM4NPC1RAB9A
SCHEMBL3923984 0.86 GRM5 (0.60) GRM5CYP2A6MKNK1GRM4NPC1
SCHEMBL5667860 0.85 CYP2A6 (0.54) GRM5CYP2A6MKNK1GRM4NPC1
SCHEMBL15945076 0.80 GRM5 (0.66) GRM5CYP2A6GRM4PDE10AKDR
SCHEMBL3919683 0.80 GRM5 (0.67) GRM5HTR1AHTR7MKNK1GRM4
SCHEMBL3921029 0.80 GRM5 (0.67) GRM5HTR1AHTR7MKNK1GRM4
SCHEMBL30795074 0.80 GRM5 (0.67) GRM5HTR1AHTR7MKNK1GRM4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-100387594-C Di-aryl substituted pyrazole modulators of metabotropic glutamate receptor-5 MERCK & CO INC (US) 2008-05-14 CN claimed
US-20060194807-A1 Di-aryl substituted pyrazole modulators of metabotropic glutamate receptor-5 MERCK & CO., INC. 2006-08-31 US claimed
CN-1795184-A Di-aryl substituted pyrazole modulators of metabotropic glutamate receptor-5 MERCK & CO INC (US) 2006-06-28 CN claimed
EP-1613614-A2 DI-ARYL SUBSTITUTED PYRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 Merck & Co., Inc. (US) 2006-01-11 EP claimed
WO-2004089303-A2 DI-ARYL SUBSTITUTED PYRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 MERCK & CO., INC. (US) 2004-10-21 WO claimed
WO-2004089303-A2 DI-ARYL SUBSTITUTED PYRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 MERCK & CO., INC. (US) 2004-10-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060194807-A1 Di-aryl substituted pyrazole modulators of metabotropic glutamate receptor-5 GRM5, GRM1, GRIK5 GRM5 1/4885CYP2A6 935/4885HTR1A 95/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.